Clinical Trial Search

Primary: Biomarkers Associated With Transfusion-Related Acute Lung Injury and Transfusion Associated Circulatory Overload. — 101; 105; 12; 15 units on a scale (pg/ml)

Primary: Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) — 5 Participants

Primary: The Incidence of Lyme Disease Among Children and Families Living in an Endemic Area Using an Educational Intervention — 1; 1 Number of cases incident Lyme disease

Primary: Incidence of Grade ≥3 Oral Mucositis Determined by Clinical Examination and Assessed by Central Review According to the Common Terminology Criteria of Adverse Events…

Primary: Time to Local Recurrence. — 28.3; 22.1; 33.3; 35.1 months — p=0.52

Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants

Primary: Overall Survival, Intention-to-treat Population — 23.9; 24.3 Months — p=0.596

Primary: Percentage of Prescribed Calories From Energy — 32; 34.2; 43.6; 33.6 percentage of prescription

Primary: Self-Ratings of Thought Appraisals (Believability) — 78.33; 77.97; 83.23; 74.74 score on a scale — p=<0.001

Primary: Baseline Adjusted Mean Change in FEV1 AUC0-24h Post Dose — 2.5644; 2.7370 L*hour

Primary: Change in Gingivitis — 0.14; 0.19 score on a scale

Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min

Primary: Numeric Pain Score — 7.5; 7; 6.3; 6.0 score on a scale

Primary: Patient Satisfaction — 100; 94 score on a scale — p==0.002

Primary: Orocaecal Transit Time — 330; 210 minutes — p=0.04